Possible new role for angiotensin-converting enzyme inhibitors in treating glomerulonephritis.
Serum transforming growth factor-beta (TGF-beta1) production was estimated for 10 patients with essential hypertension, 12 patients with glomerulonephritis (5 hypertensive and 7 normotensive) and 10 healthy controls. The glomerulonephritis group received angiotensin-converting enzyme inhibitor captopril 25-75 mg/day for 4 weeks. Blood urea, serum creatinine, 24-hour urinary protein and serum TGF-beta1 were then re-estimated. Urea and creatinine were significantly higher in the hypertension and glomerulonephritis groups than in the controls and also higher in the glomerulonephritis group than the hypertension group. TGF-beta1 was significantly higher in the glomerulonephritis groups than in the control and hypertension groups. TGF-beta1 and 24-hour urinary protein were significantly reduced in the glomerulonephritis group.
Soliman
A R
AR
Department of Internal Medicine and Clinical Pathology, Faculty of Medicine, University of Cairo, Cairo, Egypt.
el-Meligi
A A
AA
el-Semari
M
M
el-Shemi
N
N
Mahmoud
H
H
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D001806:Blood Urea Nitrogen; D002216:Captopril / Q000494:pharmacology / Q000627:therapeutic use*; D016022:Case-Control Studies; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000378:metabolism*; D007118:Immunoassay; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000652:urine; D016212:Transforming Growth Factor beta / Q000097:blood / Q000187:drug effects; D053773:Transforming Growth Factor beta1; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D002216:Captopril; D003404:Creatinine